Winners and losers from the US Inflation Reduction Act

19 August 2022

The USA’s Inflation Reduction Act, which was signed into law Tuesday afternoon, contains several provisions that affect financial service company Morningstar’s stock valuations in the clean energy and pharmaceutical industries, according to Dave Sekera, chief US market strategist for Morningstar. His analysis of the Inflation Reduction Act published on Morningstar.com: The Companies That Stand to Win and Lose From the Inflation Reduction Act.

Mr Sekera’s key takeaways from his analysis regarding the pharmaceutical aspects include:

The Act contains various measures to lower prescription drug costs which will be a modest to moderate headwind for the pharmaceutical industry, including:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK